Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy

European Journal of Heart Failure

Volumn 10, Issue 9, 2008, Pages 878-883

  Umar, Soban ^a   Bax, Jeroen J ^a   Klok, Margreet ^a   van Bommel, Rutger J ^a   Hessel, Marleen H M ^a   den Adel, Brigit ^a   Bleeker, Gabe B ^a   Henneman, Maureen M ^a   Atsma, Douwe E ^a   van der Wall, Ernst E ^a   Schalij, Martin J ^a   van der Laarse, Arnoud ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiac resynchronisation therapy; Heart failure; ICTP; PIIINP; PINP

Indexed keywords

COLLAGEN TYPE 1; ICTP PEPTIDE; PIIINP PEPTIDE; PINP PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SYSTOLE;

BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; COLLAGEN; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIUM; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 51349124714     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.06.019     Document Type: Article

References (33)

1. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and the renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
2. Laurent G.J. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 252 (1987) C1-C9
3. Fini M.E., Cook J.R., Mohan R., and Brinckerhoff C.E. Regulation of matrix metalloproteinase gene expression. In: Parks W.C., and Mecham R.P. (Eds). Matrix Metalloproteinases (1998), Academic Press, San Diego 299-362
4. Sato H., Takino T., Kinoshita T., et al. Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett 385 (1996) 238-240
5. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
6. Sakata Y., Yamamoto K., Mano T., et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats. Circulation 109 (2004) 2143-2149
7. Burlew B.S., and Weber K.T. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27 (2002) 92-98
8. Hessel M.H.M., Bleeker G.B., Bax J.J., et al. Reverse ventricular remodelling after cardiac resynchronisation therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail 9 (2007) 1058-1063
9. Bax J.J., Bleeker G.B., Marwick T.H., et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 44 (2004) 1834-1840
10. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
11. Ypenburg C., Roes S.D., Bleeker G.B., et al. Effect of total scar burden on contrast-enhanced magnetic resonance imaging on response to cardiac resynchronisation therapy. Am J Cardiol 99 (2007) 657-660
12. Yu C.M., Bleeker G.B., Fung J.W., et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 112 (2005) 1580-1586
13. Bax J.J., Marwick T.H., Molhoek S.G., et al. Left ventricular dyssynchrony predicts benefit of cardiac resynchronization therapy in patients with end-stage heart failure before pacemaker implantation. Am J Cardiol 92 (2003) 1238-1240
14. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiog 7 (2006) 79-108
15. Risteli J., Elomaa I., Niemi S., Novamo A., and Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39 (1993) 635-640
16. Garcia-Bolao I., Macias A., Lopez B., et al. A biomarker of myocardial fibrosis predicts long-term response to cardiac resynchronization therapy. J Am Coll Cardiol 47 (2006) 23335-23337
17. Melkko J., Kauppila S., Niemi S., et al. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42 (1996) 947-954
18. Risteli J., Niemi S., Trivedi P., Mäentausta O., Mowat A.P., and Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 34 (1988) 715-718
19. Plumpton T.A., Clark I.M., Plumpton C., Calvin J., and Cawston T.E. Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP-1 and CRP in serum. Clin Chim Acta 240 (1995) 137-154
20. Zhang J., Fujimoto N., Iwata K., Sakai T., Okada Y., and Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies. Clin Chim Acta 219 (1993) 1-14
21. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., and Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4 (2002) 439-444
22. Zannad F., Alla F., Dousset B., Perez A., Pitt B., and on behalf of the RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy to patients with congestive heart failure. Circulation 102 (2000) 2700-2706
23. Cicoira M., Rossi A., Bonapace S., et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 10 (2004) 403-411
24. Klappacher G., Franzen P., Haab D., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995) 913-918
25. Querejeta R., Varo N., Lopez B., et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 101 (2000) 1729-1735
26. Laviades C., Varo N., Fernandez J., et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98 (1998) 535-540
27. Zannad F., Dousset B., and Alla F. Treatment of congestive heart failure. Interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 38 (2001) 1227-1232
28. Maceira A.M., Barba J., Varo N., Beloqui O., and Diez J. Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Hypertension 39 (2002) 923-928
29. Lopez B., Gonzalez A., Varo N., Laviades C., Querejeta R., and Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 38 (2001) 1222-1226
30. Lombardi R., Betocchi S., Losi M.A., et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 108 (2003) 1455-1460
31. Rossi A., Cicoira M., Golia G., et al. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. Heart 90 (2004) 650-654
32. Li Y.Y., Feng Y., McTiernan C.F., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104 (2001) 1147-1152
33. Bruggink A.H., van Oosterhout M.F.M., de Jonge N., et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 25 (2006) 1091-1098